# ClinicalTrials.gov record NCT03466021

> PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03466021-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03466021-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03466021-liraglutide-v1.json
- Content SHA-256: `267aee79d5ab70a6f5a9b4bd71c5a8924a72d212ab1cfd6caaa78e8986a347b6`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03466021 ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

## Sources

<a id="source-ctg-observation-nct03466021-2021-03-16-252ec0730220"></a>
- **ClinicalTrials.gov record NCT03466021 · retained source version 2021-03-16:252ec0730220066aba86678666fd29420fe59adc3285d317c67d5c02dc87e64b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03466021) (`ctg-observation-nct03466021-2021-03-16-252ec0730220`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03466021." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03466021-liraglutide-v1.json SHA-256: 267aee79d5ab70a6f5a9b4bd71c5a8924a72d212ab1cfd6caaa78e8986a347b6.